An increase in clopidogrel prescriptions could be seen in the US and Europe for secondary ischaemic stroke prevention as a result of the outcomes of the Phase III POINT trial, according to data and analytics company, GlobalData.
Stroke
The standard of care (SoC) for patients with non-cardioembolic acute ischaemic stroke (AIS) and transient ischaemic attack (TIA) to reduce the risk of recurrence in the US is aspirin. However, in China it is routine practice to prescribe aspirin with another antiplatelet drug, clopidogrel, which is sold by Sanofi under the brand name Plavix.